Corvus制药公司报告说,对同位素皮肤炎药物取得了积极的中期结果,但库存下降了28%。 Corvus Pharmaceuticals reports positive interim results for atopic dermatitis drug, yet stock drops 28%.

Corvus制药公司宣布了第一阶段对Soquelitinib临床试验的临时数据,表明治疗外皮皮炎的安全性和有效性良好。 Corvus Pharmaceuticals announced interim data from a Phase 1 clinical trial for soquelitinib, showing positive safety and efficacy in treating atopic dermatitis. 审判对象包括12名药物患者和4名安慰剂患者。 The trial included 12 patients on the drug and 4 on a placebo. 尽管从Samlyn Capital收到1 270万美元,但Corvus的股票在市场前贸易中下跌了28.42%。 Despite receiving $12.7 million from Samlyn Capital, Corvus' stock fell 28.42% in pre-market trading. 该公司将在12月18日提供数据的全面概览。 The company will provide a full overview of the data on December 18.